» Articles » PMID: 25869387

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

Abstract

Purpose: The goals of the study were to elucidate the immune mechanisms that contribute to desirable complete remissions of murine colon tumors treated with single radiation dose of 30 Gy. This dose is at the upper end of the ablative range used clinically to treat advanced or metastatic colorectal, liver, and non-small cell lung tumors.

Experimental Design: Changes in the tumor immune microenvironment of single tumor nodules exposed to radiation were studied using 21-day (>1 cm in diameter) CT26 and MC38 colon tumors. These are well-characterized weakly immunogenic tumors.

Results: We found that the high-dose radiation transformed the immunosuppressive tumor microenvironment resulting in an intense CD8(+) T-cell tumor infiltrate, and a loss of myeloid-derived suppressor cells (MDSC). The change was dependent on antigen cross-presenting CD8(+) dendritic cells, secretion of IFNγ, and CD4(+)T cells expressing CD40L. Antitumor CD8(+) T cells entered tumors shortly after radiotherapy, reversed MDSC infiltration, and mediated durable remissions in an IFNγ-dependent manner. Interestingly, extended fractionated radiation regimen did not result in robust CD8(+) T-cell infiltration.

Conclusions: For immunologically sensitive tumors, these results indicate that remissions induced by a short course of high-dose radiotherapy depend on the development of antitumor immunity that is reflected by the nature and kinetics of changes induced in the tumor cell microenvironment. These results suggest that systematic examination of the tumor immune microenvironment may help in optimizing the radiation regimen used to treat tumors by adding a robust immune response.

Citing Articles

Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma.

Yin Z, Zhang H, Zhang K, Yue J, Tang R, Wang Y BMC Cancer. 2025; 25(1):474.

PMID: 40087599 DOI: 10.1186/s12885-025-13801-0.


Immunological Effects of Proton Radiotherapy: New Opportunities and Challenges in Cancer Therapy.

Zhang A, Fan L, Liu Q, Zuo X, Zhu J Cancer Innov. 2025; 4(2):e70003.

PMID: 40061827 PMC: 11885950. DOI: 10.1002/cai2.70003.


Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.

Tanigawa K, Redmond W Oncoimmunology. 2025; 14(1):2452654.

PMID: 39812092 PMC: 11740684. DOI: 10.1080/2162402X.2025.2452654.


Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.

Coles-Black J, Rahman A, Siva S, Ischia J, Perera M, Bolton D Life (Basel). 2025; 14(12.

PMID: 39768390 PMC: 11678295. DOI: 10.3390/life14121683.


Reduced irradiation exposure areas enhanced anti-tumor effect by inducing DNA damage and preserving lymphocytes.

Chen H, Li Y, Shen Q, Guo G, Wang Z, Pan H Mol Med. 2024; 30(1):284.

PMID: 39736508 PMC: 11687019. DOI: 10.1186/s10020-024-01037-w.


References
1.
Sinha P, Chornoguz O, Clements V, Artemenko K, Zubarev R, Ostrand-Rosenberg S . Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011; 117(20):5381-90. PMC: 3109712. DOI: 10.1182/blood-2010-11-321752. View

2.
Berzofsky J, Terabe M . The contrasting roles of NKT cells in tumor immunity. Curr Mol Med. 2009; 9(6):667-72. PMC: 2729783. DOI: 10.2174/156652409788970706. View

3.
Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

4.
Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

5.
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H . CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58(16):3491-4. View